Altogether, our data suggest that the pharmacological inhibition of autophagy may be a valuable approach to combat acquired resistance to ALK-tyrosine kinase inhibitor entrectinib, which we propose for a clinical evaluation in NB patients. The gene discussed is ALK; the disease is neuroblastoma.